Mounjaro

#GLP-1 #Mounjaro #Obesity #Ozempic #Weight loss

Weight-loss drugs’ challenge to pharma’s safety infrastructure

For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity, they also present an operational nightmare for companies. That's as  volumes of adverse events threaten to swamp existing safety workflows. Qinecsa’s Daniel O’Keeffe assesses the scale of the problem.  The success of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as modern weight-loss solutions has yet to… Read More

#Exclusive Content #Opinion